Alzheimer's drug pipeline

Lifestyle · Heat 1.2 / 10 · 2 shows · 30m airtime

As of September 16, 2026, lecanemab and donanemab are FDA-approved and shown in trials to clear amyloid plaque and slow cognitive decline. The discussion has since moved from the drugs themselves to access: a 12-month wait on a treatment list leaves 25 percent of MCI and 50 percent of mild dementia patients ineligible, and in the U.S. a PET scan or CSF is still required to qualify. Falsely reassuring a patient that memory loss is normal can delay diagnosis by a year and a half or more. The Alzheimer's Association's $100 million push into a possible GLP-1 link remains open.

How 2 podcasts covered it

1. Today, Explained, 2026-09-16 (14:32 to 25:41)
   Delivers the good news on amyloid and tau drugs
   Delivers the promised good news: lecanemab and donanemab clear amyloid and slow decline, tau drugs and blood tests are coming, and the Alzheimer's Association is putting $100 million into a possible GLP-1 link. Also covers an experimental Chinese brain-drain surgery whose pioneer was arrested on insurance fraud charges.
   New angle: The Alzheimer's Association is putting $100 million behind research into a possible GLP-1 link to Alzheimer's risk.
2. The Podcast by KevinMD, 2026-10-20 (1:11 to 4:50)
   Retells the approved-drugs story with a patient anecdote
   A physician explains why early diagnosis matters now that two treatments can slow Alzheimer's, arguing biomarker testing is required and comparing Alzheimer's to cancer. It retells the approved-drugs story already on the record, adding only a patient anecdote.
3. The Podcast by KevinMD, 2026-10-20 (4:42 to 9:22)
   Argues the blood test is the accessible route
   Walks through the three Alzheimer's biomarkers - amyloid PET, CSF from lumbar puncture, and the P-tau-217 blood test - and argues the blood test is the cheap, accessible route to the approved drugs. Adds a waiting-list figure: a year's delay costs eligibility for a quarter of MCI patients and half of mild AD dementia patients.
   New angle: A 12-month wait on a treatment list leaves 25 percent of MCI and 50 percent of mild AD dementia patients ineligible.
4. The Podcast by KevinMD, 2026-10-20 (9:28 to 12:31)
   Finds the gap between the blood test and access
   Walks through the P-tau-217 result bands and finds a gap between the blood test and access: in the U.S. a PET scan or CSF is still required to qualify for the licensed drugs, while the U.K. treats on a high blood result alone.
   New angle: In the U.S., a PET scan or CSF is still required to qualify for the licensed Alzheimer's drugs.
5. The Podcast by KevinMD, 2026-10-20 (12:31 to 15:14)
   Explains the biology behind the narrow window
   MacSweeney walks through the biology behind the narrow window: amyloid builds for about 20 years, triggers microgliosis, and tau then spreads exponentially, so the drugs must come before tau takes off. It explains the mechanism behind a claim already on the record rather than adding a development.
6. The Podcast by KevinMD, 2026-10-20 (15:19 to 20:04)
   Lists the early signs that should trigger a test
   MacSweeney lists the early signs that should trigger a biomarker test in primary care and warns that falsely reassuring a patient can delay diagnosis by a year and a half or more, past the treatment window.
   New angle: Falsely reassuring a patient that memory loss is normal can delay diagnosis by a year and a half or more.